Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
Information date: 10 September 2026 — A Nature Outlook article published on 10 September 2026 reviewed efforts to direct therapies to mitochondria and other subcellular structures, including the history of peptides that
信息日期：2026年9月10日 — EMA 9月1日启动新方法学自愿数据提交试点，允许企业、方法开发者、CRO和学术机构提交类器官、微生理系统、计算模型等数据并获得专家反馈；试点预计接收到2027年第三季度。 对需要据此作出经营、合规或采购决定的人来说，真正的问题不是记住一个结论，而是先确认它适用于谁、通过什么环节影响实际业务，以及哪项证据足以支持行动。 事实与适用范围 EMA 9月1日启动新方法学自愿数据提交试点，允许企业、方法开发者
Information date: 10 September 2026 — A Nature Communications article published on 2 September 2026 reported that trifluoroacetate, commonly encountered as a peptide counterion, modulated PPAR-alpha signalling, altered l
Information date: 9 September 2026 — FDA’s draft clinical-pharmacology guidance for peptide drug products highlights hepatic impairment, drug interactions, QTc risk and immunogenicity as considerations that may affect ph
Information date: 9 September 2026 — FDA announced revised draft product-specific guidances for 17 generic peptide products that address manufacturing route, innate immune response testing, impurity thresholds, higher-or
Information date: 9 September 2026 — FDA guidance pages distinguish draft recommendations from final guidance and approved product information; none of those categories is equivalent to direct evidence for an unrelated p
